It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

BofA analyst Jason Gerberry raised the firm’s price target on Jazz Pharmaceuticals (JAZZ ... trading at “highly depressed multiples,” yet offering mid-single digit sales and high-single digit bottom ...

Jefferies raised the firm’s price target on Verona Pharma (VRNA) to $45 from $38 and keeps a Buy rating on the shares. Ohtuvayre reported ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

The German pharma and ... predicted 2024 sales between 20.7 billion and 22.1 billion euros, said it was now guiding for the ...

HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

The raised stock price target to $42 per American ... remains optimistic about continued sales growth and the drug's broad prescription base. Verona Pharma's recent financial performance and ...

On Friday, Recursion Pharmaceuticals Inc (RXRX) stock saw a modest uptick, ending the day at $7.1 which represents a slight increase of $0.17 or 2.45% from the prior close of $6.93. The stock opened ...

The raised stock price target to $42 per American Depositary ... Despite the net loss for Q3, the company remains optimistic about continued sales growth and the drug's broad prescription base. Verona ...